Intraocular Melanoma in Adults | NYU Langone Health
Perlmutter Cancer Center specialists offer expert care for people with intraocular melanoma, or choroidal melanoma, a cancer that begins in the eye.
Intrathecal Therapy for Acute Myeloid Leukemia | NYU Langone Health
NYU Langone doctors may recommend intrathecal therapy to destroy leukemia cells for people with acute myeloid leukemia.
Intrathecal Therapy for Leukemia in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital recommend intrathecal therapy to protect the central nervous system during chemotherapy for acute childhood leukemia.
Intrathecal Therapy for Non-Hodgkin Lymphoma in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone use intrathecal therapy to protect the central nervous system during chemotherapy.
Intravenous Treatment for Sepsis in Children | NYU Langone Health
At Hassenfeld Children’s Hospital at NYU Langone, children with sepsis receive IV treatments to combat infection and symptoms.
Intravesical Therapy for Bladder Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use intravesical immunotherapy or intravesical chemotherapy to treat bladder cancer.
Investigating auditory processing in the users of auditory brainstem and cochlear implants
This is a basic investigational research study conducted with hearing impaired adults and children who use cochlear implant or auditory brainstem implant (ABI) devices. The study will evaluate different aspects of hearing and auditory processing in the users of implantable auditory devices.
Investigating the Temperature Dependence of Age-related Tau Pathology Relevant to Early Alzheimer's Disease
This is a cross-sectional study in 100 older adults (n = 100, 50 female, 60–80 years) who are cognitively normal (n = 70) or have mild cognitive impairment (n = 30). The purpose is to test whether features of body temperature (Tb), measured with ingestible telemetry, are associated with tau pathology, measured with [18-F]-MK-6240 tau PET-MR and plasma P-tau. Participant involvement includes 6 study visits over a period of 4 months. The duration of the project is 5 years. Briefly, subjects who express interest and are eligible for screening based on a pre-screening call will undergo in-person medical screening and complete several intake questionnaires at Visit 1, followed by a blood draw at CTSI, a clinical interview and neuropsychological testing at Visit 2. A 7-day at-home sleep assessment and actigraphy data, after Visit 2, will help us determine sleep-wake cycles and screen for Obstructive Sleep Apnea which is exclusionary for our study, if severe. At Visits 3 & 4, subjects will undergo body temperature measurements with ingestible telemetric thermometry over 48 hours, commencing on Night 1 of a 48 hour visit to the MSCIC sleep lab. Sleep EEG characteristics will be assessed with polysomnography on Nights 1 and 2 of this 48 hour period. During the day between these nights, subjects will be free to return home. After sleep study data is analyzed, the Eligibility Checklist can be completed. At Visit 5 which will take place at least 7 days after the sleep study completion, subjects will undergo a Tau PET/MR scan at the Center for Biomedical Imaging. At Visit 6, at least 7 days after the sleep study (but not on the same day as the Tau PET/MR) subjects will undergo an amyloid PET/MR scan. The purpose of the PET/MR scans is to control for tau and amyloid burden in the central nervous system.This cross-sectional study will lay the ground work for future prospective studies to determine whether Tb based interventions can prevent the progression of NFT pathology toward reducing Alzheimer’s Disease burden.
Investigation of cellular and molecular interactions in inflammation angiogenesis and immunity in human atherosclerosis: the ATHERO-IN study
Atherosclerotic cardiovascular disease (ACVD) is driven by inflammation and is the leading cause of mortality and disability worldwide, even in optimally treated patients. The impact of many immune cells (inflammatory cells) on atherosclerosis progression is well-established, the contribution of different immune and non-immune cells to human disease pathology and cardiovascular (CV) events remain largely unknown. It is well established that specific histological features of plaque instability are associated with increased risk for cardiovascular events (i.e. stroke, heart attack). This study will address the following knowledge gaps. The ATHERO-IN study is a prospective and retrospective, multisite, observational study. The study will be conducted at two study sites: 1. the NYU Langone Health (coordinating and recruitment site) and 2. the Icahn School of Medicine at Mount Sinai (recruitment site). The Focus of the study is atherosclerotic cardiovascular disease and inflammation. The Goal of the study is to identify new cellular and molecular determinant of atherosclerosis, plaque pathology and cardiovascular events. To achieve this goal, we will use a system biology approach to analyze human samples that will be obtained from patients with atherosclerotic cardiovascular disease from the NYU Langone Health System (NYULH) and from the Mount Sinai Health System (MSHS).
Investigation of Cooking Aerosol Emissions and Health Effects due to Exposure in an Occupational Cohort
Air pollution exposure can result in negative health effects. This study will look at how exposure to cooking vapors or gases in a western-style (a.k.a. American, European, or Latin) restaurant can impact worker health.